¼¼°èÀÇ CRISPR ±â¹Ý Áø´Ü¾à ½ÃÀå º¸°í¼­(2025³â)
CRISPR-Based Diagnostics Global Market Report 2025
»óǰÄÚµå : 1716936
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,319,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,134,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,949,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

CRISPR ±â¹Ý Áø´Ü¾à ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 17.9%·Î 99¾ï 2,000¸¸ ´Þ·¯·Î ¼ºÀåÇÕ´Ï´Ù. ¿¹Ãø ±â°£ Áß ¿¹»óµÇ´Â ¼ºÀåÀº ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °¨¿°¼º Áúȯ °ËÃâ¿¡ ´ëÇÑ Àû¿ë È®´ë, Á¤ºÎ ¹× ±â°üÀÇ ÀÚ±Ý Áö¿ø Áõ°¡, Ç×»ýÁ¦ ³»¼º °ËÃâ °³¼±, CRISPR ±â¼ú¿¡ ´ëÇÑ Àνİú ¼ö¿ë¼º Áõ°¡ µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ ±â°£ Áß ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ÇöÀåÁø´Ü(POC) °Ë»ç, CRISPR-Cas12 ¹× Cas13 ½Ã½ºÅÛ »ç¿ë, ¸ÂÃãÀÇ·á ¹× À¯ÀüÀÚ ½ºÅ©¸®´×ÀÇ ÁÖ¿ä ¹ßÀü, ³ª³ëÅ×Å©³î·¯Áö ¹× ¹ÙÀÌ¿À¼¾¼­¿ÍÀÇ ÅëÇÕ, CRISPR ±â¹Ý Á¶±â Áúº´ °¨Áö ¹æ¹ýÀÇ °³¹ß µîÀÌ ÀÖ½À´Ï´Ù.

°¨¿°¼º ÁúȯÀÇ ¹ßº´·ü Áõ°¡´Â CRISPR ±â¹Ý Áø´Ü ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °¨¿°¼º ÁúȯÀº ¹ÚÅ׸®¾Æ, ¹ÙÀÌ·¯½º, °õÆÎÀÌ, ±â»ýÃæ°ú °°Àº º´¿ø¼º ¹Ì»ý¹°¿¡ ÀÇÇØ ¹ß»ýÇϸç, »ç¶÷ °£ ¶Ç´Â ¿À¿°µÈ Ç¥¸é, À½½Ä, ¹°, °ïÃæ°ú °°Àº ¸Å°³Ã¼¸¦ ÅëÇØ ÀüÆÄµÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ÀÇ ¹ß»ý ºóµµ Áõ°¡´Â ¼¼°èÈ­, Ç×»ýÁ¦ ³»¼º, ±âÈÄ º¯È­, µµ½ÃÈ­, Àα¸ Áõ°¡, ¼­½ÄÁö ÆÄ±«, ÀÇ·á Á¢±Ù¼º Á¦ÇÑ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ý ºóµµ°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, CRISPR ±â¹Ý Áø´ÜÀº ½Å¼ÓÇϰí Á¤È®ÇÑ º´¿øÃ¼ °ËÃâ, Á¶±â Áø´Ü, ½Å¼ÓÇÑ °³ÀÔ, È¿°úÀûÀÎ ºÀ¼â Àü·«ÀÇ ½ÇÇöÀ» ÅëÇØ °¨¿°º´ ÅðÄ¡¸¦ Áö¿øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 8¿ù ¿µ±¹ ÇàÁ¤±â°üÀÎ UK Health Security Agency(UKHSA)ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2023³â ¿µ±¹¿¡¼­ 368°ÇÀÇ È«¿ª ȯÀÚ°¡ º¸°íµÈ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ´Â 2022³â 53°Ç¿¡¼­ 7¹è °¡±îÀÌ Áõ°¡ÇÑ °ÍÀ¸·Î, ¿þ½ºÆ®¹Ìµé·£µå°¡ 44%, ·±´øÀÌ 33%¸¦ Â÷ÁöÇß½À´Ï´Ù. °á°úÀûÀ¸·Î °¨¿°¼º ÁúȯÀÇ ¹ß»ý·ü Áõ°¡°¡ CRISPR ±â¹Ý Áø´Ü¾à ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

CRISPR ±â¹Ý Áø´Ü ½ÃÀå ÁÖ¿ä ±â¾÷Àº CRISPR ±â¹Ý ÇöÀå Áø´ÜÀ» ÅëÇØ ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±Çϱâ À§ÇØ Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ü°áÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àü·«Àû ÆÄÆ®³Ê½ÊÀº °øµ¿ÀÇ ¸ñÇ¥¸¦ ´Þ¼ºÇÏ°í °æÀï·ÂÀ» °­È­Çϱâ À§ÇØ ÀÚ¿ø°ú Àü¹®¼ºÀ» °áÁýÇÏ´Â Á¶Á÷ °£ÀÇ Àå±âÀûÀÎ Çù·Â °ü°è¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 8¿ù Àεµ¿¡ º»»ç¸¦ µÐ »ý¸í°øÇÐ ±â¾÷ CrisprBits Private Limited´Â ÀεµÀÇ ºÐÀÚÁø´Ü ȸ»ç Molbio Diagnostics¿Í Àü·«Àû Á¦ÈÞ¸¦ ¸Î¾ú½À´Ï´Ù. À̹ø Á¦ÈÞ´Â º´¿øÃ¼ ¹× À¯ÀüÀÚ ¸¶Ä¿¸¦ °ËÃâÇϱâ À§ÇÑ ½Å¼ÓÇϰí Á¤È®ÇÏ¸ç ºñ¿ë È¿À²ÀûÀÎ Áø´Ü ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â CRISPR ±â¹Ý POCT(Point-of-Care Test) °³¹ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. CrisprBitsÀÇ CRISPR Ç÷§Æû¿¡ ´ëÇÑ Àü¹®¼º°ú MorbioÀÇ Á¦Á¶ ¹× ÆÇ¸Å ¿ª·®À» °áÇÕÇÏ¿©, CrisprBitsÀÇ CRISPR Ç÷§Æû Àü¹®¼º°ú MorbioÀÇ Á¦Á¶ ¹× ÆÇ¸Å ¿ª·®À» °áÇÕÇÔÀ¸·Î½á, À̹ø Á¦ÈÞ´Â ÀÌ·¯ÇÑ °Ë»ç¸¦ Àü ¼¼°è ½ÃÀå¿¡ Ãâ½ÃÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå¿¡ µµÀÔÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ½ÃÀåÀÇ Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª¹ÙÀÌ·¯½ºÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ´ë±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÇÕº´°ú Àμö

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

CRISPR-based diagnostics refers to advanced molecular tools that utilize the CRISPR-Cas system to detect specific nucleic acid sequences with high precision and speed, enabling the identification of diseases or genetic markers. This technology offers groundbreaking capabilities in medical and genomic analysis. CRISPR-based diagnostics are used in applications such as detecting infectious diseases, identifying genetic disorders, and monitoring mutations in cancer research and treatment. It also holds significant potential in personalized medicine and point-of-care testing.

The primary products in CRISPR-based diagnostics include kits, buffer solutions, software, and other components. CRISPR diagnostic kits are ready-to-use tools designed for the rapid and accurate detection of specific genetic material, frequently applied in disease diagnosis and research. Techniques used in this process include recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), and others. These diagnostics are used for both infectious and non-infectious diseases and are employed by hospitals, diagnostic centers, biotechnology companies, academic and research institutions, among others.

The CRISPR-based diagnostics market research report is one of a series of new reports from The Business Research Company that provides CRISPR-based diagnostics market statistics, including CRISPR-based diagnostics industry global market size, regional shares, competitors with CRISPR-based diagnostics market share, detailed CRISPR-based diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the CRISPR-based diagnostics industry. This CRISPR-based diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The CRISPR-based diagnostics market size has grown rapidly in recent years. It will grow from $4.35 billion in 2024 to $5.14 billion in 2025 at a compound annual growth rate (CAGR) of 18.1%. The growth observed during the historic period can be attributed to factors such as an increase in healthcare expenditure, a rising demand for gene editing, a higher prevalence and incidence of chronic diseases, growing awareness of available treatments, and a rise in the prevalence of genetic disorders.

The CRISPR-based diagnostics market size is expected to see rapid growth in the next few years. It will grow to $9.92 billion in 2029 at a compound annual growth rate (CAGR) of 17.9%. The growth projected for the forecast period can be attributed to factors such as the increasing demand for rapid and accurate diagnostics, expanding applications in infectious disease detection, rising government and institutional funding, improved detection of antibiotic resistance, and growing awareness and acceptance of CRISPR technologies. Key trends anticipated during this period include point-of-care (POC) testing, the use of CRISPR-Cas12 and Cas13 systems, advancements in personalized medicine and genetic screening, integration with nanotechnology and biosensors, and the development of CRISPR-based early disease detection methods.

The growing incidence of infectious diseases is expected to drive the expansion of the CRISPR-based diagnostics market. Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, which can spread from person to person or through contaminated surfaces, food, water, or vectors such as insects. The rising frequency of these diseases is attributed to factors including globalization, antibiotic resistance, climate change, urbanization, population growth, habitat destruction, and limited access to healthcare. CRISPR-based diagnostics support the fight against infectious diseases by offering rapid and accurate pathogen detection, enabling early diagnosis, prompt intervention, and effective containment strategies. For example, in August 2024, data from the UK Health Security Agency (UKHSA), a UK-based executive agency, revealed that 368 measles cases were reported in England in 2023. This represented a nearly sevenfold increase from the 53 cases in 2022, with the West Midlands and London accounting for 44% and 33% of the cases, respectively. As a result, the increasing incidence of infectious diseases is driving the growth of the CRISPR-based diagnostics market.

Major players in the CRISPR-based diagnostics market are increasingly forming strategic partnerships to improve access to rapid and accurate diagnostics through CRISPR-based point-of-care tests. A strategic partnership involves a long-term collaboration between organizations that combine their resources and expertise to achieve shared goals and strengthen their competitive edge. For example, in August 2023, CrisprBits Private Limited, a biotechnology company based in India, entered into a strategic collaboration with Molbio Diagnostics, an Indian molecular diagnostics company. This partnership focuses on developing CRISPR-based point-of-care tests (POCTs) that offer rapid, precise, and cost-effective diagnostic solutions for detecting pathogens and genetic markers. The goal is to enhance diagnostic accessibility in various environments, including resource-limited areas, while ensuring quick and accurate disease detection. By combining CrisprBits' CRISPR platform expertise with Molbio's manufacturing and distribution capabilities, the collaboration aims to introduce these tests to a global market.

In February 2024, Ginkgo Bioworks Holdings Inc., a biotechnology company based in the United States, acquired Proof Diagnostics Inc. for an undisclosed amount. The acquisition is intended to enhance Ginkgo's gene therapy services by incorporating Proof Diagnostics' OMEGA RNA-programmable nuclease technology, thereby improving its gene editing capabilities. This strategic move strengthens Ginkgo's ability to offer advanced solutions in therapeutic development and precision gene editing. Proof Diagnostics Inc. is a US-based company that specializes in CRISPR-based molecular testing solutions for COVID-19.

Major players in the crispr-based diagnostics market are Thermo Fisher Scientific Inc., Integrated DNA Technologies Inc., Molbio Diagnostics, Horizon Discovery, Beam Therapeutics, Intellia Therapeutics Inc., Synthego Corporation, Caribou Biosciences, Mammoth Biosciences, Verve Therapeutics, Editas Medicine, Epic Bio, Sherlock Biosciences, Addgene, VedaBio, CrisprBits, SNIPR BIOME ApS, TOLO Biotech, Intact Genomics, Agdia Inc., and ToolGen Inc.

North America was the largest region in the CRISPR-based diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in CRISPR-based diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the CRISPR-based diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CRISPR-based diagnostics market includes revenues earned by entities by providing services such as diagnostic testing services, custom CRISPR assays development, screening and surveillance services, and regulatory and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR-based diagnostics market also consists of sales of CRISPR-based RNA detection systems, CRISPR-based monitoring tools, lateral flow assays, and CRISPR-based test platforms. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CRISPR-Based Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on crispr-based diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for crispr-based diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The crispr-based diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. CRISPR-Based Diagnostics Market Characteristics

3. CRISPR-Based Diagnostics Market Trends And Strategies

4. CRISPR-Based Diagnostics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global CRISPR-Based Diagnostics Growth Analysis And Strategic Analysis Framework

6. CRISPR-Based Diagnostics Market Segmentation

7. CRISPR-Based Diagnostics Market Regional And Country Analysis

8. Asia-Pacific CRISPR-Based Diagnostics Market

9. China CRISPR-Based Diagnostics Market

10. India CRISPR-Based Diagnostics Market

11. Japan CRISPR-Based Diagnostics Market

12. Australia CRISPR-Based Diagnostics Market

13. Indonesia CRISPR-Based Diagnostics Market

14. South Korea CRISPR-Based Diagnostics Market

15. Western Europe CRISPR-Based Diagnostics Market

16. UK CRISPR-Based Diagnostics Market

17. Germany CRISPR-Based Diagnostics Market

18. France CRISPR-Based Diagnostics Market

19. Italy CRISPR-Based Diagnostics Market

20. Spain CRISPR-Based Diagnostics Market

21. Eastern Europe CRISPR-Based Diagnostics Market

22. Russia CRISPR-Based Diagnostics Market

23. North America CRISPR-Based Diagnostics Market

24. USA CRISPR-Based Diagnostics Market

25. Canada CRISPR-Based Diagnostics Market

26. South America CRISPR-Based Diagnostics Market

27. Brazil CRISPR-Based Diagnostics Market

28. Middle East CRISPR-Based Diagnostics Market

29. Africa CRISPR-Based Diagnostics Market

30. CRISPR-Based Diagnostics Market Competitive Landscape And Company Profiles

31. CRISPR-Based Diagnostics Market Other Major And Innovative Companies

32. Global CRISPR-Based Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The CRISPR-Based Diagnostics Market

34. Recent Developments In The CRISPR-Based Diagnostics Market

35. CRISPR-Based Diagnostics Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â